glp-1 clinical trials recruiting 📣 NOW RECRUITING: New Research Study We are looking for participants for a Phase 3 trial evaluating a new weight-management option! If you've been on a stable (either Current Insights, Advantages and Challenges

For instance, in June 2024, Boehringer Ingelheim and Zealand Pharma reported notable efficacy of survodutide, their dual agonist targeting GLP-1 and glucagon receptors, in reducing liver fibrosis among patients with metabolic dysfunction-associated steatohepatitis (MASH)

The clinical benefits of TESAMORELIN include its effectiveness in reducing visceral fat and improving metabolic health in patients with HIV-associated lipodystrophy

Possible side effects include mild nausea, bloating, or gastrointestinal upset

These agents include semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), while tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist